Hanyu Pharmaceutical's HY3000 nasal spray obtained the ethical approval of the phase II clinical trial team leader

On December 02, 2022, the phase II clinical research protocol of HY3000 nasal spray of Shenzhen Hanyu Pharmaceutical Co.
, Ltd.
was approved by the team leader of the Medical Ethics Committee of Zhujiang Hospital of Southern Medical University (approval number: 2022-YW-075-02).

This study is a randomized, double-blind, placebo-controlled phase II clinical study
evaluating the efficacy and safety of HY3000 nasal spray for pre-exposure prophylaxis against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection.
The phase II clinical research protocol has recently been submitted to the medical ethics committee of Zhujiang Hospital of Southern Medical University for review and approval
.

HY3000 is a membrane fusion inhibitor polypeptide that acts on the HR1 region of the new coronavirus spike protein, and by binding to the HR1 region, prevents the formation of the virus hexahelix bundle structure and blocks the path
of virus infection cells.
The dosage form developed in this project is nasal spray, which can establish an antiviral defense line on the primary path of virus invasion of the human body through nasal administration, and block the new coronavirus infection
.